美国 · 财经报刊 · Investor's Business Daily
Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test
Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study, the company said Wednesday. The post Lilly's Reta Trounces Novo…
在 Investor's Business Daily 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.investors.com)
